整理 | GLP1减重宝典内容团队丹麦制药巨头诺和诺德终于迎来了一次久违的市场反弹。随着其口服版Wegovy在美国市场正式上市并取得超预期的首周表现,资本市场迅速给出了正反馈。根据IQVIA数据,口服Wegovy在1月5日上市后的第一周处方量约为3100份,而Symphony的追踪数据显示这一数字甚至可能达到4290份,显著高于竞争对手 礼来 旗下肥胖症明星产品Zepbound在上市首周仅1300...
Source Link整理 | GLP1减重宝典内容团队丹麦制药巨头诺和诺德终于迎来了一次久违的市场反弹。随着其口服版Wegovy在美国市场正式上市并取得超预期的首周表现,资本市场迅速给出了正反馈。根据IQVIA数据,口服Wegovy在1月5日上市后的第一周处方量约为3100份,而Symphony的追踪数据显示这一数字甚至可能达到4290份,显著高于竞争对手 礼来 旗下肥胖症明星产品Zepbound在上市首周仅1300...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.